Pavel Kapysh / Shutterstock.com
13 August 2019AmericasSarah Morgan
Sandoz to appeal against Amgen biosimilar ruling
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
3 March 2016 Amgen and Sandoz are set to go head to head in another patent case, this time centring on Amgen’s arthritis treatment drug Enbrel.
Americas
9 December 2014 Novartis’s generic arm Sandoz has failed to win a patent case regarding its biosimilar version of Amgen’s psoriasis and arthritis drug Enbrel (etanercept).
Editor's picks
Editor's picks
Americas
3 March 2016 Amgen and Sandoz are set to go head to head in another patent case, this time centring on Amgen’s arthritis treatment drug Enbrel.
Americas
9 December 2014 Novartis’s generic arm Sandoz has failed to win a patent case regarding its biosimilar version of Amgen’s psoriasis and arthritis drug Enbrel (etanercept).
Americas
3 March 2016 Amgen and Sandoz are set to go head to head in another patent case, this time centring on Amgen’s arthritis treatment drug Enbrel.
Americas
9 December 2014 Novartis’s generic arm Sandoz has failed to win a patent case regarding its biosimilar version of Amgen’s psoriasis and arthritis drug Enbrel (etanercept).